ZA971808B - Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans - Google Patents

Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans

Info

Publication number
ZA971808B
ZA971808B ZA971808A ZA971808A ZA971808B ZA 971808 B ZA971808 B ZA 971808B ZA 971808 A ZA971808 A ZA 971808A ZA 971808 A ZA971808 A ZA 971808A ZA 971808 B ZA971808 B ZA 971808B
Authority
ZA
South Africa
Prior art keywords
treating chronic
arteriosclerosis obliterans
containing medicament
carnitine derivative
chronic arteriosclerosis
Prior art date
Application number
ZA971808A
Other languages
English (en)
Inventor
Marco Corsi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ZA971808B publication Critical patent/ZA971808B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
ZA971808A 1996-03-04 1997-03-03 Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans ZA971808B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96830093A EP0793962B1 (de) 1996-03-04 1996-03-04 Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans

Publications (1)

Publication Number Publication Date
ZA971808B true ZA971808B (en) 1998-07-31

Family

ID=8225823

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA971808A ZA971808B (en) 1996-03-04 1997-03-03 Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans

Country Status (13)

Country Link
US (1) US5811457A (de)
EP (1) EP0793962B1 (de)
JP (1) JPH09323927A (de)
KR (1) KR100346883B1 (de)
AT (1) ATE187329T1 (de)
CA (1) CA2198833C (de)
DE (1) DE69605531T2 (de)
DK (1) DK0793962T3 (de)
ES (1) ES2141463T3 (de)
GR (1) GR3032903T3 (de)
PT (1) PT793962E (de)
TW (1) TW349863B (de)
ZA (1) ZA971808B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
CA2350071A1 (en) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
AU1258699A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
CN1646515A (zh) * 2002-04-18 2005-07-27 中外制药株式会社 用于改善血管内皮血管张力调节功能的医药组合物
US7776913B2 (en) * 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006061341A1 (en) * 2004-12-10 2006-06-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a high-dose medicament for the treatment of peripheral arterial disease
US7560485B2 (en) * 2005-10-04 2009-07-14 Sigma-Tau Industrie Parmaceutiche Riunite S.P.A. Method for treating intermittent claudication comprising the administration of propionyl L-carnitine and a concomitant physical training
EP2353596A1 (de) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Kombinationszusammensetzung mit L-Carnitin oder Proponyl-L-Carnitin als Wirkstoffe zur Vorbeugung oder Behandlung von chronischer Veneninsuffizienz
SG185692A1 (en) 2010-06-16 2013-01-30 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
US9114120B2 (en) 2010-11-22 2015-08-25 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Therapeutical method for the treatment of the Leber optic neuropathy
WO2012076352A1 (en) 2010-12-09 2012-06-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for topical use for treating skin disorders
EP2783695A1 (de) 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Physiologische Ergänzung oder Medikament zur ophthalmischen Verwendung mit L-Carnitin oder Alkanoyl-L-Carnitinen in Kombination mit Eledoisin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease

Also Published As

Publication number Publication date
ES2141463T3 (es) 2000-03-16
MX9701294A (es) 1997-09-30
JPH09323927A (ja) 1997-12-16
TW349863B (en) 1999-01-11
DE69605531T2 (de) 2000-05-31
CA2198833C (en) 2003-07-22
ATE187329T1 (de) 1999-12-15
KR970064602A (ko) 1997-10-13
EP0793962B1 (de) 1999-12-08
KR100346883B1 (ko) 2003-01-06
PT793962E (pt) 2000-05-31
DE69605531D1 (de) 2000-01-13
US5811457A (en) 1998-09-22
DK0793962T3 (da) 2000-05-22
EP0793962A1 (de) 1997-09-10
GR3032903T3 (en) 2000-07-31
CA2198833A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
ZA971808B (en) Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans
CA2258895A1 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
SI0654264T1 (en) Use of venlafaxine or of an aryloxy propanamine compound for the manufacture of a medicament for the treatment of urinary incontinence
AU4658489A (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma
ZA921292B (en) Treatment of lower urinary tract disorders.
CA2228281A1 (en) Use of l-carnitine and acyl l-carnitines for lowering ceramide levels
EP0279887A3 (en) Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
HK1005847A1 (en) Use of acetyl l-carnitine in the therapeutic treatment of coma
CA2297153A1 (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
GB2284440B (en) A machine installation for treating the ballast bed of a track
MX9703810A (es) Medicamento que comprende un derivado de carnitinapara tratar la enfermedad de alzheimer en pacientes con inicio prematuro.
AU670491C (en) Pharmaceutical for the treatment of skin disorders
GB2262052B (en) Process for the treatment of a waste water stream
GB2288420B (en) A machine for treating the ballast bed of a track with a suction tube
AU3279993A (en) A device for the treatment/purification of sewage-effluent
ZA947912B (en) Treatment of medical disorders associated with free radical formation
SI0836853T1 (en) Use of bradykinin antagonists for the manufacture of a medicament for treating Alzheimer's disease
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
IT1240779B (it) Impiego di l-carnitina nel trattamento delle miopatie funzionali laringee.
FI953725A (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
IT1241589B (it) Mezzi per il trattamento terapeutico dell'apnea durante il sonno
RU96120518A (ru) Средство для лечения больных хроническим простатитом
BG98001U (en) Medicament for the treatment of hyperkeratotic conditions of the skin
PL303802A1 (en) Elastic head bandage for producing a therapeutic effect